Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-000993
Filing Date
2025-03-28
Accepted
2025-03-27 17:38:13
Documents
85
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1527044
2 ex4-7.htm EX-4.7 34672
3 ex19.htm EX-19 108754
4 ex21.htm EX-21 9790
5 ex31-1.htm EX-31.1 16256
6 ex31-2.htm EX-31.2 16324
7 ex32.htm EX-32 6688
  Complete submission text file 0001641172-25-000993.txt   7596873

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE pvct-20241231.xsd EX-101.SCH 56886
9 XBRL CALCULATION FILE pvct-20241231_cal.xml EX-101.CAL 70751
10 XBRL DEFINITION FILE pvct-20241231_def.xml EX-101.DEF 206058
11 XBRL LABEL FILE pvct-20241231_lab.xml EX-101.LAB 509737
12 XBRL PRESENTATION FILE pvct-20241231_pre.xml EX-101.PRE 385108
88 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1119700
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36457 | Film No.: 25780763
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)